newsfilter
← Latest News
GlobeNewswire·

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported were consistent